Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CYRX
CYRX logo

CYRX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
13.680
Open
12.770
VWAP
13.30
Vol
838.01K
Mkt Cap
685.47M
Low
12.610
Amount
11.14M
EV/EBITDA(TTM)
--
Total Shares
50.40M
EV
513.79M
EV/OCF(TTM)
--
P/S(TTM)
3.72
Cryoport, Inc. is a provider of integrated, temperature-controlled supply chain solutions for the life sciences. The Company operates through two segments: segments: Life Sciences Services and Life Sciences Products. Its life sciences services include BioLogistics and BioStorage/BioServices, which provides temperature-controlled logistics, biostorage and bioservices within the life science industry through direct sales. Its life sciences products segment manufactures and sells cryogenic systems, such as freezers and cryogenic dewars and related ancillary accessories used in the storage and transport of life science commodities through direct sales or a distribution network. Its operating units include Cryoport Systems, CryoGene and MVE Biological Solutions (MVE). Cryoport Systems provides temperature-controlled BioLogistics, BioServices, and cryopreservation solutions, supporting clinical and commercial workflows through transport, kit production, labeling, packaging, and others.
Show More

Events Timeline

(ET)
2026-05-04
16:30:00
Cryoport Reports Q1 Revenue of $47.8M
select
2026-03-03 (ET)
2026-03-03
16:20:00
Cryoport Q4 Revenue $45.45M Exceeds Expectations
select
2026-03-03
16:20:00
Cryoport Sees FY26 Revenue of $190.0M-$194.0M
select
2025-11-04 (ET)
2025-11-04
16:43:58
Cryoport increases FY25 revenue forecast to $170.0M-$174.0M, up from $165M-$172M
select

News

seekingalpha
9.5
05-05seekingalpha
Cryoport Reports Strong Q1 2026 Earnings Growth
  • Significant Revenue Growth: Cryoport reported Q1 revenue of $47.8 million, a 16% year-over-year increase, with commercial cell and gene therapy revenue rising 26% to $9.1 million, underscoring the company's market leadership and robust demand.
  • Innovative Clinical Trial Support: As of March 31, Cryoport supported a record 766 global clinical trials, including 91 in Phase III, reflecting the company's strong influence in the biopharmaceutical sector and the ongoing growth in market demand.
  • Optimistic Outlook: The company raised its full-year 2026 revenue guidance to $192 million to $196 million, expecting to achieve positive adjusted EBITDA in the second half of the year, indicating management's confidence in future performance and market potential.
  • Product and Service Expansion: Cryoport introduced its new Fusion 800 series and successfully shipped its first cryopreserved clinical trial materials from its Houston and Belgium facilities to clients, marking significant progress in product delivery and market expansion.
moomoo
9.5
05-04moomoo
CRYOPORT Q1 REVENUE REACHES USD 47.8 MILLION, EXCEEDING IBES ESTIMATE OF USD 44.9 MILLION
  • Revenue Comparison: Cryoport reported a revenue of USD 47.8 million for Q1, exceeding the estimated revenue of USD 44.9 million by Ibes.
  • Financial Performance: The significant difference between actual revenue and estimates indicates a strong performance by Cryoport in the first quarter.
seekingalpha
9.5
05-01seekingalpha
CryoPort to Announce Q1 Earnings on May 4th
  • Earnings Announcement Date: CryoPort (CYRX) is set to announce its Q1 earnings on May 4th after market close, with a consensus EPS estimate of -$0.19, reflecting a 32.1% year-over-year improvement, indicating potential for enhanced profitability.
  • Revenue Growth Expectations: Analysts project Q1 revenue of $44.86 million, representing a 9.3% year-over-year increase, suggesting that the company is making strides in the commercialization of cell therapies, which could lay the groundwork for future growth.
  • Performance Against Estimates: Over the past year, CryoPort has only beaten EPS and revenue estimates 25% of the time, highlighting challenges in managing market expectations and potentially affecting investor confidence.
  • Estimate Revision Trends: In the last three months, EPS estimates saw no upward revisions and three downward adjustments, while revenue estimates experienced five upward revisions and two downward adjustments, indicating market divergence and uncertainty regarding CryoPort's future performance.
PRnewswire
9.5
04-20PRnewswire
Cryoport to Announce Q1 2026 Financial Results on May 4
  • Earnings Release Schedule: Cryoport will report its Q1 2026 financial results on May 4, 2026, after U.S. market close, providing a comprehensive review of the company's financial and operational performance to keep investors informed.
  • Conference Call Details: On the same day at 5:00 PM ET, Cryoport's management will host a Q&A conference call to address investor inquiries regarding the reported results, with a slide deck to enhance communication effectiveness.
  • Replay Availability: A recording of the Q&A session will be available approximately three hours after the live event on the company's website, and a dial-in replay will be accessible until May 11, 2026, ensuring that investors who missed the live call can still obtain the information.
  • Global Business Overview: Cryoport focuses on integrated temperature-controlled supply chain solutions for life sciences, supporting biopharmaceutical companies and research institutions, and aims to enhance business reliability and agility through innovation and regulatory compliance.
Benzinga
6.5
03-04Benzinga
Wall Street Analysts Adjust Ratings
  • Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
  • Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of SMTC stock, as these insights may affect investor confidence and willingness to buy, directly impacting stock prices.
  • Source of Updates: A complete view of all analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a comprehensive perspective to help investors make informed decisions.
  • Market Dynamics Impact: The adjustments in analysts' ratings not only reflect views on company fundamentals but may also influence overall market sentiment, subsequently affecting trading volumes and price fluctuations of related stocks.
seekingalpha
9.5
03-04seekingalpha
Cryoport Exceeds 2025 Revenue Guidance with Strong Growth
  • Revenue Growth Highlight: Cryoport reported $176.2 million in revenue from continuing operations for 2025, exceeding the high end of prior guidance, which reflects sustained momentum across core markets and is expected to bolster investor confidence.
  • Segment Performance: In Q4, commercial cell and gene therapy revenue grew 29% year-over-year to $33.4 million, while clinical trial revenue increased 14% to $47.1 million, indicating strong performance in the rapidly evolving biopharmaceutical sector.
  • Strategic Investments and Partnerships: The company made strategic investments in its Global Supply Chain Centers in Paris and California, alongside new collaborations with DHL, Cardinal Health, and Parexel, which will lay the groundwork for future market expansion and enhanced service capabilities.
  • Future Outlook: Management anticipates full-year 2026 revenue guidance of $190 million to $194 million and aims to achieve positive adjusted EBITDA in the second half of 2026, demonstrating confidence in future growth and a continued focus on commercial cell therapy.
Wall Street analysts forecast CYRX stock price to rise
1 Analyst Rating
Wall Street analysts forecast CYRX stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
11.00
Averages
11.00
High
11.00
Current: 0.000
sliders
Low
11.00
Averages
11.00
High
11.00
Needham
Buy
maintain
$13 -> $15
AI Analysis
2026-05-05
Reason
Needham
Price Target
$13 -> $15
AI Analysis
2026-05-05
maintain
Buy
Reason
Needham raised the firm's price target on Cryoport to $15 from $13 and keeps a Buy rating on the shares.
Guggenheim
Subbu Nambi
Buy
maintain
$11 -> $12
2026-05-05
Reason
Guggenheim
Subbu Nambi
Price Target
$11 -> $12
2026-05-05
maintain
Buy
Reason
Guggenheim analyst Subbu Nambi raised the firm's price target on Cryoport to $12 from $11 and keeps a Buy rating on the shares. After what the firm calls "a clean first quarter," Guggenheim thinks it was prudent of management to remain conservative given geopolitical uncertainty, the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CYRX
Unlock Now

Valuation Metrics

The current forward P/E ratio for Cryoport Inc (CYRX.O) is 68.03, compared to its 5-year average forward P/E of -65.69. For a more detailed relative valuation and DCF analysis to assess Cryoport Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-65.69
Current PE
68.03
Overvalued PE
87.38
Undervalued PE
-218.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.12
Current EV/EBITDA
-36.88
Overvalued EV/EBITDA
115.35
Undervalued EV/EBITDA
-121.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.44
Current PS
3.02
Overvalued PS
7.86
Undervalued PS
1.03

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

give me best stocks to night trade tonight
Intellectia · 84 candidates
Market Cap: >= 500.00MVolume: >= 500,000Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceCrossAboveMA20Is Optionable: TrueMonthly Average Dollar Volume: >= 300,000News Driver: Positive
Ticker
Name
Market Cap$
top bottom
EVER logo
EVER
EverQuote Inc
842.59M
STRL logo
STRL
Sterling Infrastructure Inc
24.73B
DOCN logo
DOCN
DigitalOcean Holdings Inc
15.94B
VRDN logo
VRDN
Viridian Therapeutics Inc
1.93B
BLDP logo
BLDP
Ballard Power Systems Inc
1.31B
IART logo
IART
Integra Lifesciences Holdings Corp
1.03B
surging stocks between 10 to $20
Intellectia · 547 candidates
Price: $10.00 - $20.00Moving Average Relationship: PriceAboveMA20
Ticker
Name
Market Cap$
top bottom
FSEA logo
FSEA
First Seacoast Bancorp Inc
78.21M
VRDN logo
VRDN
Viridian Therapeutics Inc
1.93B
BDSX logo
BDSX
Biodesix Inc
151.02M
AIOS logo
AIOS
AIOS Tech Inc
63.69M
ONEG logo
ONEG
OneConstruction Group Ltd
175.36M
IART logo
IART
Integra Lifesciences Holdings Corp
1.03B
stocks to buy right now for day trading
Intellectia · 416 candidates
Region: USPrice: >= $2.00Volume: >= 2,000,000Price Change Pct: >= $0.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA5, PriceAboveMA20Is Optionable: True
Ticker
Name
Market Cap$
top bottom
BLZE logo
BLZE
Backblaze Inc
278.47M
EVC logo
EVC
Entravision Communications Corp
351.59M
AURA logo
AURA
Aura Biosciences Inc
536.07M
CYTK logo
CYTK
Cytokinetics Inc
8.21B
EVER logo
EVER
EverQuote Inc
516.80M
STRC logo
STRC
Strategy Inc
64.49B
day trading where do i go
Intellectia · 429 candidates
Price: $2.00 - $100.00Price Change Pct: >= $0.00Relative Vol: >= 1.50Beta: HighRiskMoving Average Relationship: PriceAboveMA5Week Price Change Pct: >= $0.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
CLRB logo
CLRB
Cellectar Biosciences Inc
12.00M
BLZE logo
BLZE
Backblaze Inc
278.47M
AURA logo
AURA
Aura Biosciences Inc
536.07M
CYTK logo
CYTK
Cytokinetics Inc
8.21B
VRDN logo
VRDN
Viridian Therapeutics Inc
1.45B
EVER logo
EVER
EverQuote Inc
516.80M

Whales Holding CYRX

B
Brown Capital Management, LLC
Holding
CYRX
+4.20%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Cryoport Inc (CYRX) stock price today?

The current price of CYRX is 13.6 USD — it has increased 6.58

What is Cryoport Inc (CYRX)'s business?

Cryoport, Inc. is a provider of integrated, temperature-controlled supply chain solutions for the life sciences. The Company operates through two segments: segments: Life Sciences Services and Life Sciences Products. Its life sciences services include BioLogistics and BioStorage/BioServices, which provides temperature-controlled logistics, biostorage and bioservices within the life science industry through direct sales. Its life sciences products segment manufactures and sells cryogenic systems, such as freezers and cryogenic dewars and related ancillary accessories used in the storage and transport of life science commodities through direct sales or a distribution network. Its operating units include Cryoport Systems, CryoGene and MVE Biological Solutions (MVE). Cryoport Systems provides temperature-controlled BioLogistics, BioServices, and cryopreservation solutions, supporting clinical and commercial workflows through transport, kit production, labeling, packaging, and others.

What is the price predicton of CYRX Stock?

Wall Street analysts forecast CYRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYRX is11.00 USD with a low forecast of 11.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cryoport Inc (CYRX)'s revenue for the last quarter?

Cryoport Inc revenue for the last quarter amounts to 47.80M USD, increased 16.47

What is Cryoport Inc (CYRX)'s earnings per share (EPS) for the last quarter?

Cryoport Inc. EPS for the last quarter amounts to -0.25 USD, decreased -10.71

How many employees does Cryoport Inc (CYRX). have?

Cryoport Inc (CYRX) has 684 emplpoyees as of May 11 2026.

What is Cryoport Inc (CYRX) market cap?

Today CYRX has the market capitalization of 685.47M USD.